Letrozole

ApprovedUNKNOWN

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.

Conditions

is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.

Trial Timeline

Feb 1, 2009 → —

NCT ID

NCT01908556

About Letrozole

Letrozole is a approved stage product being developed by Novartis for is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.. The current trial status is unknown. This product is registered under clinical trial identifier NCT01908556. Target conditions include is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients..

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01908556	Approved	UNKNOWN	Feb 1, 2009	—	is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
NCT00856050	Phase 2	Completed	Feb 1, 2009	Mar 1, 2014	Leiomyosarcoma
NCT00688909	Approved	Completed	Mar 1, 2008	Jun 1, 2009	Breast Cancer
NCT00549822	Phase 2	Terminated	Oct 1, 2007	Sep 1, 2013	Breast Cancer
NCT00414076	Phase 2	Terminated	Dec 19, 2006	Jul 13, 2017	Leiomyosarcoma
NCT00382070	Phase 3	Active	Aug 1, 2006	Apr 1, 2025	Breast Cancer
NCT00332852	Phase 3	Completed	Mar 1, 2006	—	Breast Cancer
NCT00330317	Phase 3	Completed	Feb 1, 2006	Nov 16, 2010	Breast Cancer
NCT00329940	Phase 3	Completed	Nov 1, 2005	—	Breast Cancer
NCT00171808	Phase 2	Completed	Apr 1, 2005	—	Endometrial Cancer
NCT00237133	Approved	Completed	Mar 1, 2003	Jan 21, 2009	Locally Advanced Breast Cancer
NCT00237224	Approved	Completed	Feb 1, 2003	—	Breast Cancer
NCT00291135	Phase 2	Completed	Jan 1, 2003	Oct 1, 2008	Breast Cancer
NCT00240942	Phase 2	Completed	Oct 1, 2002	Jun 1, 2006	Severe and Recurrent Endometriosis
NCT00333047	Phase 2/3	Completed	Jul 1, 2002	—	Metastatic Breast Cancer
NCT00241046	Approved	Terminated	Apr 1, 2002	—	Metastatic Breast Cancer
NCT00014638	Approved	Completed	Jan 1, 2001	Mar 1, 2002	Breast Cancer
NCT00535418	Phase 2/3	Completed	Jun 1, 2000	—	Breast Cancer
NCT00333086	Phase 2	Completed	Jan 1, 2000	—	Recurrent and Metastatic Endometrial Cancer

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved